Tomohiro Suzumura

Summary

Affiliation: Osaka City University
Country: Japan

Publications

  1. pmc Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer
    Tomohiro Suzumura
    Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan
    BMC Cancer 12:568. 2012
  2. ncbi request reprint Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population
    Tomohiro Suzumura
    Department of Respiratory Medicine, Osaka City University, Graduate School of Medicine, Japan
    Osaka City Med J 58:25-34. 2012
  3. ncbi request reprint Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs
    Kanako Umekawa
    Department of Respiratory Medicine, Osaka City University, Graduate School of Medicine, Japan
    Osaka City Med J 59:53-60. 2013
  4. ncbi request reprint Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations
    Misato Nagata
    Department of Respiratory Medicine, Osaka City University, Graduate School of Medicine, Japan
    Osaka City Med J 59:45-52. 2013
  5. ncbi request reprint Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer
    Shigeki Mitsuoka
    Department of Respiratory Medicine, Osaka City University, Graduate School of Medicine, Japan
    Osaka City Med J 57:59-66. 2011
  6. pmc Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs
    Kanako Umekawa
    Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, 1 4 3 Asahi machi, Abeno Ku, Osaka 545 8585, Japan
    BMC Res Notes 6:139. 2013
  7. pmc C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin
    Misato Nagata
    Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University
    Clin Med Insights Oncol 7:31-9. 2013
  8. doi request reprint Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs
    Hidenori Tanaka
    Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Abeno Ku, Osaka, Japan
    Int J Cancer 129:1410-6. 2011

Detail Information

Publications8

  1. pmc Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer
    Tomohiro Suzumura
    Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan
    BMC Cancer 12:568. 2012
    ..It has been hypothesized that CYP2D6 phenotypes may be implicated in different adverse events associated with gefitinib and erlotinib therapies...
  2. ncbi request reprint Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population
    Tomohiro Suzumura
    Department of Respiratory Medicine, Osaka City University, Graduate School of Medicine, Japan
    Osaka City Med J 58:25-34. 2012
    ..It has been hypothesized that gefitinib therapy results in different adverse events compared to erlotinib therapy...
  3. ncbi request reprint Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs
    Kanako Umekawa
    Department of Respiratory Medicine, Osaka City University, Graduate School of Medicine, Japan
    Osaka City Med J 59:53-60. 2013
    ..Previously, we reported that high levels of plasma HGF at diagnosis indicated intrinsic resistance to EGFR-TKIs. EGFR-TKIs have been hypothesized to affect these adipokines...
  4. ncbi request reprint Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations
    Misato Nagata
    Department of Respiratory Medicine, Osaka City University, Graduate School of Medicine, Japan
    Osaka City Med J 59:45-52. 2013
    ..We assessed the SREs in advanced lung adenocarcinoma patients that evaluated EGFR mutations in whom bone metastasis was present...
  5. ncbi request reprint Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer
    Shigeki Mitsuoka
    Department of Respiratory Medicine, Osaka City University, Graduate School of Medicine, Japan
    Osaka City Med J 57:59-66. 2011
    ..The objective of this retrospective analysis was to evaluate the efficacy and safety of AMR as second-line chemotherapy in SCLC, especially refractory relapsed SCLC...
  6. pmc Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs
    Kanako Umekawa
    Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, 1 4 3 Asahi machi, Abeno Ku, Osaka 545 8585, Japan
    BMC Res Notes 6:139. 2013
    ..EGFR-TKIs have been found to affect this network of pro-inflammatory cytokines...
  7. pmc C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin
    Misato Nagata
    Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University
    Clin Med Insights Oncol 7:31-9. 2013
    ..NADPH quinone oxidoreductase 1 (NQO1) metabolizes the quinone structures contained in both amrubicin (AMR) and amrubicinol (AMR-OH). We hypothesized that 1 C609T polymorphism may affect AMR-related pharmacokinetics and clinical outcomes...
  8. doi request reprint Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs
    Hidenori Tanaka
    Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Abeno Ku, Osaka, Japan
    Int J Cancer 129:1410-6. 2011
    ..Plasma hepatocyte growth factor can serve as a useful biomarker for the early diagnosis of tumor relapse treated with epidermal growth factor receptor tyrosine kinase inhibitors...